Detalles de la búsqueda
1.
Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.
Respir Res
; 23(1): 272, 2022 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36183104
2.
Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.
Pulm Circ
; 14(1): e12310, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38205098
3.
Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension.
Pulm Circ
; 13(2): e12213, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37025209
4.
Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group.
Pulm Circ
; 13(4): e12317, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-38144948
5.
Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.
Pulm Circ
; 12(4): e12178, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36578976
6.
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.
Pulm Circ
; 12(3): e12127, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36016668
Resultados
1 -
6
de 6
1
Próxima >
>>